AtriCure, Inc. (ATRC) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRC trades at $30.91 with a market cap of $1.44B and a P/E ratio of -288.90. ATRC moved +0.69% today. Year to date, ATRC is -28.43%; over the trailing twelve months it is -14.83%. Its 52-week range spans $25.52 to $43.18. Analyst consensus is strong buy with an average price target of $50.29. Rallies surfaces ATRC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AtriCure Tops Q3 Revenue Estimates, Forecasts 109% FY2026 Earnings Growth: AtriCure reported a third-quarter 2025 adjusted loss of $0.01 per share, narrower by 90.9% from expectations, while revenue of $134.3 million exceeded consensus by 2.1%. The company projects a 109.1% earnings growth rate for fiscal 2026, far outpacing the 15.8% industry average.
| Metric | Value |
|---|---|
| Price | $30.91 |
| Market Cap | $1.44B |
| P/E Ratio | -288.90 |
| EPS | $-0.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.18 |
| 52-Week Low | $25.52 |
| Volume | 171 |
| Avg Volume | 0 |
| Revenue (TTM) | $552.16M |
| Net Income | $-4.59M |
| Gross Margin | 75.61% |
8 analysts cover ATRC: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.29.